Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment
Glucocorticoids (GC) are diffusely used to treat a wide variety of inflammatory and autoimmune disorders, including rheumatic diseases. GC-induced osteoporosis (GIO) is the most common and serious side-effect for patients receiving GC. Loss of bone mineral density (BMD) is greatest in the first few...
Main Authors: | Andrea Delle Sedie, Ombretta Di Munno |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-09-01
|
Series: | Reumatismo |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/244 |
Similar Items
-
Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios
by: A. Delle Sedie, et al.
Published: (2011-09-01) -
Glucocorticoid-induced osteoporosis in rheumatic diseases
by: Rosa Maria Rodrigues Pereira, et al.
Published: (2010-01-01) -
GLUCOCORTICOID-INDUCED OSTEOPOROSIS: PATHOGENESIS, PREVENTION, TREATMENT
by: Irina Aleksandrovna Baranova
Published: (2010-06-01) -
Glucocorticoid-induced osteoporosis: pathogenesis and prevention
by: I. G. Krasivina, et al.
Published: (2020-01-01) -
Glucocorticoid-induced osteoporosis: 2013 update
by: M. Mazzantini, et al.
Published: (2014-07-01)